This clinical trial is focused on studying the effects of a medication called finerenone on kidney health, specifically looking at how it affects oxidative stress in the blood vessels of the kidneys. Oxidative stress is a condition where there is an imbalance between free radicals and antioxidants in the body, which can lead to cell damage. The study involves participants who have type 2 diabetes mellitus, a common condition where the body does not use insulin properly, leading to high blood sugar levels.
Participants in the study will receive either Kerendia (finerenone) in the form of film-coated tablets or a placebo, which looks like the medication but does not contain any active ingredients. The study will also use a diagnostic agent called aminohippuric acid and a contrast agent known as iohexol to help assess kidney function. Additionally, L-arginine hydrochloride and ascorbic acid (commonly known as Vitamin C) will be used during the study to further understand their effects on kidney health.
The purpose of the study is to determine how finerenone impacts oxidative stress in the kidneys by observing changes in kidney blood flow after Vitamin C is given, compared to the placebo. Participants will take part in the study over a period of time, during which they will receive the study medication or placebo and undergo various assessments to monitor their kidney health and overall well-being.
Germany 
